Document is current

Any future updates will be listed below

Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma

Crossref DOI link: https://doi.org/10.1007/s11096-021-01372-6

Published Online: 2022-01-28

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark